Searchable abstracts of presentations at key conferences in endocrinology

ea0050ecp1.2 | (1) | SFEBES2017

The role of hypoxia in the physiology and pathology of menstruation

Maybin Jacqueline , Murray Alison , Hirani Nikhil , Saunders Philippa , Carmeliet Peter , Critchley Hilary

Heavy menstrual bleeding (HMB) is common and debilitating but it remains a taboo subject. Hence its cause remains undefined, resulting in non-specific hormone therapies with intolerable side effects.Over 70 years ago it was proposed that progesterone withdrawal caused intense vasoconstriction and a transient endometrial hypoxia that resulted in menstruation. Subsequent research confirmed that inflammation initiated menses and disputed the role of hypoxia...

ea0050p272 | Neuroendocrinology and Pituitary | SFEBES2017

The severity of obstructive sleep apnoea does not influence ambient IGF-I levels

Lynch Julie , Kyriakakis Nikolaos , Elliott Mark , Ghosh Dipansu , Nix Mitchell , Watts Sue , Murray Robert D

Introduction: Obstructive sleep apnoea (OSA) is reported to have effects on a number of hormone systems including glycaemic control, catecholamines, and the HPA axis. In this study we aimed to determine the impact of OSA on IGF-I levels.Patients & Methods: This is a prospective cohort study performed at Leeds Teaching Hospitals. Patients were recruited from the Sleep Apnoea Clinic between November 2014 and May 2...

ea0050p286 | Neuroendocrinology and Pituitary | SFEBES2017

Acromegaly complication screening – are we meeting the guidelines?

Sifontes-Dubon Mildred , Bhatt Dhruti , Murray Lynne , Phull Perminder , Graveling Alex , Philip Sam , Abraham Prakash

Aims: Endocrine Society (ES) acromegaly guidelines (2014) addressed complication screening. Uncontrolled acromegaly is associated with elevated cardiovascular mortality due to risk factors including hypertension (HT), diabetes mellitus (DM), obstructive sleep apnoea (OSA), and with an increased risk of colorectal cancer and polyps among other types of neoplasias. We audited our clinical practice with regards to acromegaly complication screening.Methods: ...

ea0050p292 | Neuroendocrinology and Pituitary | SFEBES2017

The burden of arthropathy in acromegaly: results from an observational study

Kyriakakis Nikolaos , Lynch Julie , Orme Steve M , Gilbey Stephen G , Conaghan Philip , Murray Robert D

Introduction: Patients with acromegaly are often left with long-term sequelae, among which arthropathy is the most common. Studies have shown impaired quality of life (QoL) in patients with acromegaly, even after long-term remission. Arthropathy is a negative predictive factor of QoL, due to its impact on physical symptoms and functioning.Patients/Methods: To characterise further the extent of the acromegalic arthop...

ea0050ecp1.2 | (1) | SFEBES2017

The role of hypoxia in the physiology and pathology of menstruation

Maybin Jacqueline , Murray Alison , Hirani Nikhil , Saunders Philippa , Carmeliet Peter , Critchley Hilary

Heavy menstrual bleeding (HMB) is common and debilitating but it remains a taboo subject. Hence its cause remains undefined, resulting in non-specific hormone therapies with intolerable side effects.Over 70 years ago it was proposed that progesterone withdrawal caused intense vasoconstriction and a transient endometrial hypoxia that resulted in menstruation. Subsequent research confirmed that inflammation initiated menses and disputed the role of hypoxia...

ea0050p272 | Neuroendocrinology and Pituitary | SFEBES2017

The severity of obstructive sleep apnoea does not influence ambient IGF-I levels

Lynch Julie , Kyriakakis Nikolaos , Elliott Mark , Ghosh Dipansu , Nix Mitchell , Watts Sue , Murray Robert D

Introduction: Obstructive sleep apnoea (OSA) is reported to have effects on a number of hormone systems including glycaemic control, catecholamines, and the HPA axis. In this study we aimed to determine the impact of OSA on IGF-I levels.Patients & Methods: This is a prospective cohort study performed at Leeds Teaching Hospitals. Patients were recruited from the Sleep Apnoea Clinic between November 2014 and May 2...

ea0050p286 | Neuroendocrinology and Pituitary | SFEBES2017

Acromegaly complication screening – are we meeting the guidelines?

Sifontes-Dubon Mildred , Bhatt Dhruti , Murray Lynne , Phull Perminder , Graveling Alex , Philip Sam , Abraham Prakash

Aims: Endocrine Society (ES) acromegaly guidelines (2014) addressed complication screening. Uncontrolled acromegaly is associated with elevated cardiovascular mortality due to risk factors including hypertension (HT), diabetes mellitus (DM), obstructive sleep apnoea (OSA), and with an increased risk of colorectal cancer and polyps among other types of neoplasias. We audited our clinical practice with regards to acromegaly complication screening.Methods: ...

ea0050p292 | Neuroendocrinology and Pituitary | SFEBES2017

The burden of arthropathy in acromegaly: results from an observational study

Kyriakakis Nikolaos , Lynch Julie , Orme Steve M , Gilbey Stephen G , Conaghan Philip , Murray Robert D

Introduction: Patients with acromegaly are often left with long-term sequelae, among which arthropathy is the most common. Studies have shown impaired quality of life (QoL) in patients with acromegaly, even after long-term remission. Arthropathy is a negative predictive factor of QoL, due to its impact on physical symptoms and functioning.Patients/Methods: To characterise further the extent of the acromegalic arthop...

ea0090p149 | Pituitary and Neuroendocrinology | ECE2023

Is a 20% decrease in free T4 (fT4) levels a reliable marker of secondary hypothyroidism in patients with non-functioning pituitary macroadenoma (NFPA)?

McLaren David , Mitchell Ellen , Z Safdar Nawaz , Gibbons Stephen , D Murray Robert

Background: Central hypothyroidism can be difficult to diagnose as TSH values often reside within the normal range. The Endocrine Society clinical guideline for hormone replacement in hypopituitarism suggests levothyroxine is indicated for treatment of secondary hypothyroidism where fT4 levels decrease by ≥20%. To determine the reliability of this biochemical marker of secondary hypothyroidism we evaluated evolution of TFTs over time within a cohort of NFPA.<p class=...

ea0065p143 | Endocrine Neoplasia and Endocrine Consequences of Living with and Beyond Cancer | SFEBES2019

Ipilimumab-induced hypophysitis: a longitudinal analysis in a cohort of patients with metastatic melanoma

Seejore Khyatisha , Osborn Djoah , Lynch Julie M , Marples Maria , Murray Robert D

Introduction: Ipilimumab is a human monoclonal antibody directed against cytotoxic T-lymphocyte antigen-4 (CTLA-4) that has been shown to significantly improve survival in patients with metastatic melanoma. Immune-related adverse events (irAEs) occur in some patients with increased T-cell activation, of which ipilimumab-related hypophysitis (IH) is an important treatment complication. The aim of this study is to determine the incidence of IH and characterise clinical presentat...